A Spotlight on the Growing Companies in the Cannabis Market

August 8, 2019 (Investorideas.com Newswire) The cannabis market is growing exponentially as more states and countries legalize the plant. Global spending on legalization is expected to grow to be a $31.3 billion market by 2022. That's 230% growth since 2017 estimates of $9.5 billion. As more states in the United States focus on the issue of legalization, this market will continue to grow. Canada legalized the drug in 2018, and many U.S. states had legalization on the ballot in 2018. The state of federal legalization will continue to impact the industry, but here are a few companies to keep an eye on.

Aurora Cannabis Inc. - ACB

Aurora Cannabis is a Canadian company that acquired rival MedReleaf in a $250 million deal. Aurora and MedReleaf produce over 570,000kg of cannabis through nine factories in Canada and one in Denmark.

Green Growth Brands - GGBXF

Green Growth Brands is a retail-focused conglomerate with several brands under one house. Most recently the company struck a deal with retailer American Eagle Outfitters and Abercrombie & Fitch to sell CBD products in-store. GGB focuses on creating skincare and beauty products that are infused with cannabinoids. GGB hopes its recent acquisition of Spring Oaks will attract investment, as that move has worked out well for Aurora Cannabis in Canada. Spring Oaks is a medical marijuana dispensary in the state of Florida. Green Growth Brands hopes to grow its presence and brand recognition across the state of Florida.

Cronos Group Inc. - CRON

Cronos Group is another Canadian cannabis cultivator with a focus on medical marijuana. Cronos also serves the international market with products shipped to Germany and a joint venture in Australia. Cronos Group has stayed out of the U.S. market because of uncertainty surrounding federal legalization. It is worth keeping an eye on how the conversation around federal legalization proceeds and if Cronos Group jumps in.

GW Pharmaceuticals - GWPH

Not all companies in the industry are focused on growing or retail products for consumers. GW Pharmaceuticals recently created a drug the FDA has approved for the treatment of seizures. Epidiolex is derived from an active ingredient in cannabis, rather than synthetically derived cannabinoids. The company is also working on additional cannabis-derived drugs to treat two rare but severe forms of epilepsy. If approved, these drugs could change the lives of people with Lennox-Gastaut syndrome and Dravet syndrome.

Innovative Industrial Properties Inc. - IIPR

To reap lucrative growth from the industry doesn't require a direct investment in growing or retail. Innovative Industrial Properties leases industrial properties for medical production. The company owns properties in Maryland, Minnesota, Arizona, California, Pennsylvania, and New York. As the legalization march continues across the United States, IIPR is buying old properties to be refurbished. IIPR is a prime investment opportunity for someone to make an ancillary profit from the industry without owning cannabis stocks.

General Cannabis Corp - CANN

Cannabis companies rely on other companies to help them get their merchandise. General Cannabis Corp owns a specialty brand while offering real estate, consulting, and business development to those in the industry. CANN also addresses security concerns for most retailers in the industry, since it is primarily cash-based.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. This article is paid for published third party content and not the content of Investorideas.com . Learn more about posting your articles at http://www.investorideas.com/Advertise/

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp